Is Titan Pharmaceuticals Stock a Good Investment?
Titan Pharmaceuticals Investment Advice | TTNP |
- Examine Titan Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Titan Pharmaceuticals' leadership team and their track record. Good management can help Titan Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Titan Pharmaceuticals' business and its evolving consumer preferences.
- Compare Titan Pharmaceuticals' performance and market position to its competitors. Analyze how Titan Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Titan Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Titan Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Titan Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Titan Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Titan Pharmaceuticals Stock
Researching Titan Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 45.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.87. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Titan Pharmaceuticals recorded a loss per share of 6.64. The entity last dividend was issued on the 1st of December 2020. The firm had 1:20 split on the 9th of January 2024.
To determine if Titan Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Titan Pharmaceuticals' research are outlined below:
| Titan Pharmaceuticals generated a negative expected return over the last 90 days | |
| Titan Pharmaceuticals has high historical volatility and very poor performance | |
| Titan Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 184 K. Net Loss for the year was (5.57 M) with loss before overhead, payroll, taxes, and interest of (4.37 M). | |
| Titan Pharmaceuticals currently holds about 6.42 M in cash with (7.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Titan Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Mcnab James R of 200000 shares of Titan Pharmaceuticals at 0.25 subject to Rule 16b-3 |
Titan Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Titan Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Titan Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Titan Pharmaceuticals Target Price Consensus
Titan target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Titan Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Titan analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Titan stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Titan Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTitan Pharmaceuticals Target Price Projection
Titan Pharmaceuticals' current and average target prices are 3.78 and 7.00, respectively. The current price of Titan Pharmaceuticals is the price at which Titan Pharmaceuticals is currently trading. On the other hand, Titan Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Titan Pharmaceuticals Market Quote on 1st of December 2024
Target Price
Analyst Consensus On Titan Pharmaceuticals Target Price
Titan Pharmaceuticals Analyst Ratings
Titan Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Titan Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Titan Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Titan Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Titan Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Titan Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Titan Pharmaceuticals backward and forwards among themselves. Titan Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Titan Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | St Germain D J Co Inc | 2024-09-30 | 1.0 | Westside Investment Management, Inc. | 2024-06-30 | 1.0 | Ubs Group Ag | 2024-06-30 | 1.0 | Cape Investment Advisory, Inc. | 2024-06-30 | 1.0 | Fmr Inc | 2024-09-30 | 0.0 | Bb&t Corp. | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 11.1 K | Tower Research Capital Llc | 2024-06-30 | 717 | Mcf Advisors, Llc | 2024-06-30 | 165 | Bank Of America Corp | 2024-06-30 | 17.0 | Group One Trading, Lp | 2024-06-30 | 12.0 |
Titan Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.34 M.Market Cap |
|
Titan Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.72) | |
| Return On Capital Employed | (1.10) | (1.15) | |
| Return On Assets | (0.69) | (0.72) | |
| Return On Equity | (0.84) | (0.88) |
Determining Titan Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Titan Pharmaceuticals is a good buy. For example, gross profit margin measures Titan Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Titan Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Titan Pharmaceuticals' management efficiency
Titan Pharmaceuticals has return on total asset (ROA) of (1.7263) % which means that it has lost $1.7263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6899) %, meaning that it created substantial loss on money invested by shareholders. Titan Pharmaceuticals' management efficiency ratios could be used to measure how well Titan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/01/2024, Return On Tangible Assets is likely to drop to -0.72. In addition to that, Return On Capital Employed is likely to drop to -1.15. As of 12/01/2024, Non Current Liabilities Other is likely to grow to about 1 M, while Total Current Liabilities is likely to drop slightly above 1.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.83 | 8.39 | |
| Tangible Book Value Per Share | 8.83 | 8.39 | |
| Price Book Value Ratio | 0.93 | 0.89 | |
| Price Fair Value | 0.93 | 0.89 | |
| Enterprise Value | -731.9 K | -695.3 K |
Leadership effectiveness at Titan Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 1.125 |
Basic technical analysis of Titan Stock
As of the 1st of December, Titan Pharmaceuticals has the Variance of 12.27, risk adjusted performance of (0.14), and Coefficient Of Variation of (521.67). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Titan Pharmaceuticals, as well as the relationship between them.Titan Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Titan Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Titan Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Titan Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Titan Pharmaceuticals' Outstanding Corporate Bonds
Titan Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Titan Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Titan bonds can be classified according to their maturity, which is the date when Titan Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| US88830MAM47 Corp BondUS88830MAM47 | View |
Understand Titan Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Titan Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 2.81 | |||
| Coefficient Of Variation | (521.67) | |||
| Standard Deviation | 3.5 | |||
| Variance | 12.27 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.88) | |||
| Total Risk Alpha | (1.27) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 16.21 | |||
| Value At Risk | (6.54) | |||
| Potential Upside | 4.43 | |||
| Skewness | 0.1076 | |||
| Kurtosis | (0.12) |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (0.44) | |||
| Mean Deviation | 2.81 | |||
| Coefficient Of Variation | (521.67) | |||
| Standard Deviation | 3.5 | |||
| Variance | 12.27 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (0.88) | |||
| Total Risk Alpha | (1.27) | |||
| Treynor Ratio | (0.45) | |||
| Maximum Drawdown | 16.21 | |||
| Value At Risk | (6.54) | |||
| Potential Upside | 4.43 | |||
| Skewness | 0.1076 | |||
| Kurtosis | (0.12) |
Consider Titan Pharmaceuticals' intraday indicators
Titan Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Titan Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Titan Pharmaceuticals Corporate Filings
8K | 27th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 15th of November 2024 Other Reports | ViewVerify | |
F3 | 21st of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
10Q | 15th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Titan Stock media impact
Far too much social signal, news, headlines, and media speculation about Titan Pharmaceuticals that are available to investors today. That information is available publicly through Titan media outlets and privately through word of mouth or via Titan internal channels. However, regardless of the origin, that massive amount of Titan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Titan Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Titan Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Titan Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Titan Pharmaceuticals alpha.
Titan Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Titan Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Titan Pharmaceuticals Corporate Management
| Brian Crowley | Senior Administration | Profile | |
| Joe Schrei | Executive Operations | Profile | |
| Marc MD | Ex Director | Profile | |
| David Lazar | Principal Officer | Profile |
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.